‘Art of the Brain’ Raises Funds for Brain Cancer Research at UCLA

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

LOS ANGELES-Diagnosed with a life-threatening brain tumor 8 years ago, Mario del Valle chose not to be physically defeated. His artist mother, Pilar del Valle, helped inspire him to learn to use his left hand. Mr. del Valle, born in Colombia and now living in Northridge, California, overcame vision and other obstacles to produce watercolors such as the two shown above. Mr. del Valle is a participant in the UCLA Neuro-Oncology Program’s Art of the Brain, which encourages brain cancer patients and their caregivers to use creativity to regain self-worth and personal power. Timothy Cloughsey, MD, is director of the UCLA Neuro-Oncology Program

LOS ANGELES—Diagnosed with a life-threatening brain tumor 8 years ago, Mario del Valle chose not to be physically defeated. His artist mother, Pilar del Valle, helped inspire him to learn to use his left hand. Mr. del Valle, born in Colombia and now living in Northridge, California, overcame vision and other obstacles to produce watercolors such as the two shown above. Mr. del Valle is a participant in the UCLA Neuro-Oncology Program’s Art of the Brain, which encourages brain cancer patients and their caregivers to use creativity to regain self-worth and personal power. Timothy Cloughsey, MD, is director of the UCLA Neuro-Oncology Program

Art of the Brain was founded by brain cancer survivor Judi Kaufman to raise funds for advanced brain cancer research. Last year, Art of the Brain sponsored a festival that featured art from brain cancer patients and their caregivers alongside the work of world-renowned artists. This year’s event, Music from the Heart (October 7), will showcase brain cancer patients in musical performances.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.